Surgery Today

, Volume 45, Issue 10, pp 1263–1270 | Cite as

Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

  • Takekazu Iwata
  • Shigetoshi Yoshida
  • Kaoru Nagato
  • Takahiro Nakajima
  • Hidemi Suzuki
  • Tetsuzo Tagawa
  • Teruaki Mizobuchi
  • Satoshi Ota
  • Yukio Nakatani
  • Ichiro Yoshino
Original Article

Abstract

Purpose

Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated.

Methods

Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls.

Results

Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021).

Conclusions

PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.

Keywords

Acute exacerbation Idiopathic pulmonary fibrosis Lung cancer Surgery Pirfenidone 

References

  1. 1.
    Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136:1357–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Yoshimura K, Miyamoto A, Uruga H, Morokawa N, Beika Y, Kishi K. A nation-wide survey on prophylaxis for acute exacerbation of idiopathic pulmonary fibrosis following lung surgery for associated lung cancer (in Japanese with English abstract). The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2008. 2009:77–81.Google Scholar
  5. 5.
    Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–7.CrossRefPubMedGoogle Scholar
  6. 6.
    King TE Jr, Bradfold WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, ASCEND Study Group, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Kawabata Y, Hoshi E, Ubukata M, Takayanagi N, Sugita Y, Aoyama K, et al. Histological changes are background factors in acute exacerbation of usual interstitial pneumonia pattern/lesions following lung resection (in Japanese with English abstract). Haigan (Jpn J Lung Cancer). 2006;46:329–36.CrossRefGoogle Scholar
  9. 9.
    Matsubara O, Ohba T, Ninomiya H, Ishikawa Y, Mark E. Histological characteristics in the prediction of acute exacerbation of idiopathic pulmonary fibrosis (IPF) following surgery for primary lung cancer. Mod Pathol. 2009;22:358A.Google Scholar
  10. 10.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedGoogle Scholar
  11. 11.
    Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax. 2010;65:70–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88:396–404.CrossRefPubMedGoogle Scholar
  14. 14.
    Chiba H, Natsuzaka M, Shiratori M, Mori M, Takahashi H. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido (in Japanese with English abstract). The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2010. 2011:143–51.Google Scholar
  15. 15.
    Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85:326–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2013;61:578–607.CrossRefPubMedGoogle Scholar
  17. 17.
    Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011;71:70–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6:1242–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132:1652–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Kumar P, Goldstraw P, Yamada K, Nicholson AG, Wells AU, Hansell DM, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125:1321–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Hoshikawa Y, Kondo T. Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection (in Japanese with English abstract). Nihon Geka Gakkai Zasshi (Jpn J Surg). 2004;105:757–62.Google Scholar
  22. 22.
    Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resction for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Sugiura H, Takeda A, Hoshi T, Kawabata Y, Sayama K, Jinzaki M, et al. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg. 2012;93:937–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg. 2008;34:878–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Shintani Y, Ohta M, Iwasaki T, Ikeda N, Tomita E, Kawahara K, et al. Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer. Gen Thorac Cardiovasc surg. 2010;58:182–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41:e161–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Maniwa T, Isaka M, Nakagawa K, Ohde Y, Okumura T, Endo M, et al. Chest-tube drainage is a sign of acute exacerbation of interstitial lung disease associated with lung cancer. Surg Today. 2013;43:408–11.CrossRefPubMedGoogle Scholar
  29. 29.
    Maniwa T, Endo M, Isaka M, Nakagawa K, Ohde Y, Okumura T, et al. Acute exacerbation of interstitial lung disease with lung cancer after surgery: evaluation with 2-[18]-fluoro-2-deoxy-d-glucose positron emission tomography. Surg Today. 2014;44:494–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc surg. 2013;61:254–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367–73.PubMedGoogle Scholar
  32. 32.
    Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, CAPACITY Study Group, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Yano M, Sasaki H, Moriyama S, Hikosaka Y, Yokota K, Kobayashi S, et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg. 2012;14:146–50.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338:1845–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1680–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Takekazu Iwata
    • 1
  • Shigetoshi Yoshida
    • 1
  • Kaoru Nagato
    • 1
  • Takahiro Nakajima
    • 1
  • Hidemi Suzuki
    • 1
  • Tetsuzo Tagawa
    • 1
  • Teruaki Mizobuchi
    • 1
  • Satoshi Ota
    • 2
  • Yukio Nakatani
    • 2
  • Ichiro Yoshino
    • 1
  1. 1.Department of General Thoracic SurgeryChiba University Graduate School of MedicineChibaJapan
  2. 2.Department of Diagnostic PathologyChiba University Graduate School of MedicineChibaJapan

Personalised recommendations